Biokeys Pharmaceuticals Inc. Hires Chief Technical Officer.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--March 14, 2003 Biokeys Pharmaceuticals Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BKYS) is pleased to announce that Dr. Joan M. Robbins will join the company as chief technical officer. Dr. Robbins will be responsible for all phases of clinical development, manufacturing, and regulatory affairs necessary to advance the company's antiviral and anticancer product portfolio. Dr. Robbins will also coordinate external research and development and manage government grant programs. Dr. Robbins was previously employed at Immusol Inc., a biopharmaceutical company specializing in anticancer and antiviral therapeutics in addition to neurodegenerative diseases and inflammation. At Immusol, she held several positions, including vice president, product development, senior director, product development, and director, therapeutics. Dr. Robbins has directed drug discovery resulting in the advancement of drug candidates into Phase I, II and III human trials, including the development of protocols with the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for clinical trials. She has also led programs for formulation, manufacturing, toxicology and pharmacology development. From 1994 to 1995, she was a research scientist and project leader for Cancer Research at Chiron Corp., where she developed y-IFN recombinant retroviral immuno-gene therapy for cancer, assays for clinical evaluation in Phase I, and tk-recombinant retroviral gene therapy for brain tumors. From 1992 to 1993, Dr. Robbins was a Post Graduate Researcher at University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. , where she developed a novel DNA-based immunotherapeutic for treatment of Her2/neu expressing tumors. From 1990 to 1991, she was a Research Fellow at the Garvin Institute for Medical Research, Centre for Immunology in Sydney, Australia, and from 1981 to 1989, Dr. Robbins was a Microbiologist at the Laboratory of Tumor Immunology and Biology at National Cancer Institute, Bethesda, Md. "We are pleased to have Dr. Robbins join our staff as chief technical officer," commented Nicholas Virca, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Biokeys Pharmaceuticals. "She brings a breadth of technical expertise, and hands-on clinical experience that will enable the Company to move toward approvals to begin human testing of our HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. viral entry inhibitor (BlockAide/CR(TM)) and HIV therapeutic vaccine (EradicAide(TM)) later this year. In addition, Dr. Robbins will oversee a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II for CoFactor cofactor An atom, organic molecule, or molecular group that is necessary for the catalytic activity (see catalysis) of many enzymes. A cofactor may be tightly bound to the protein portion of an enzyme and thus be an integral part of its functional structure, or it may (TM), which has already been approved for front-line therapy testing in metastatic colorectal cancer patients in the U.S." Dr. Robbins' background in drug discovery and development has resulted in over 20 scientific publications and 5 patents. Dr. Robbins received her B.S. degree in genetics from the University of California, Davis The University of California, Davis, commonly known as UC Davis, is one of the ten campuses of the University of California, and was established as the University Farm in 1905. , and a Ph.D. degree in genetics from George Washington University George Washington University, at Washington, D.C.; coeducational; chartered 1821 as Columbian College (one of the first nonsectarian colleges), opened 1822, became a university in 1873, renamed 1904. , Washington D.C. More information about Biokeys Pharmaceuticals can be found on the Web site at www.bkys.com. If you would like to receive email alerts on the company, please send your request to info@bkys.com. About BKYS Biokeys Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The company is focusing its resources in anticancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. . The company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. |
|
|||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion